Clinical Laserthermia Systems AB Class B (LS60) Price & Analysis

LS60 Stock Chart & Stats

€0.11€0.00(0.00%)

At close: Oct 30 4:00 PM EDT

Day’s Range: EUR 0.11 - EUR 0.11
52-Week Range: EUR 0.11 - EUR 0.90
Previous Close: EUR 0.11
Volume: 0
Average Volume (3M): 0
Market Cap: EUR 7.76M
Enterprise Value: EUR 100.00M
Total Cash (Recent Filing): EUR 3.87M
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: 0.06
Next Earnings: Nov 13, 2026
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

A debt-free capital structure materially reduces refinancing and interest risks, giving management flexibility to prioritize commercialization or R&D. Over months this improves solvency and lowers fixed financing costs, providing runway to execute a turnaround without near-term debt obligations.

Installed-base Recurring Revenue

The platform-plus-consumables model creates durable recurring revenue once systems are installed. Consumables and service provide higher-margin, repeatable sales and customer stickiness, supporting steady revenue per installed site and improving lifetime customer value as adoption grows.

Niche, Image-guided Minimally Invasive Therapy

CLS operates in a structural growth segment: minimally invasive, image-guided oncology therapies. Specialized technology tied to imaging modalities creates higher technical barriers and clinical switching costs, supporting a defendable niche and potential adoption tailwinds from broader minimally invasive procedure trends.

Bears Say

Declining Revenue And Negative Margins

Sustained revenue decline and a shift to negative gross margins indicate persistent under-absorption of fixed costs, pricing or mix pressure, and weak demand. These dynamics make achieving sustainable profitability difficult without durable volume recovery or structural cost reductions.

Material Negative Cash Flow

Chronic negative operating and free cash flow create ongoing cash burn, forcing dependence on external financing. Over months this constrains investments in sales, clinical evidence, and product development, risks dilution from equity raises, and limits the company’s ability to scale commercial operations.

Asset Contraction And Poor Capital Returns

Declining asset base plus negative ROE signal shrinking operational scale and inefficient capital deployment. Persistent losses erode reinvestment capacity, making it harder to rebuild commercial footprint or fund clinical programs, prolonging recovery timelines absent a clear profitability path.

LS60 FAQ

What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?

Clinical Laserthermia Systems AB Class B lowest stock price was €0.11 and its highest was €0.90 in the past 12 months.

What is Clinical Laserthermia Systems AB Class B’s market cap?

Clinical Laserthermia Systems AB Class B’s market cap is €7.76M.

When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?

Clinical Laserthermia Systems AB Class B released its earnings results on Jul 17, 2026. The company reported -€0.035 earnings per share for the quarter.

Is Clinical Laserthermia Systems AB Class B overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Clinical Laserthermia Systems AB Class B pay dividends?

Clinical Laserthermia Systems AB Class B does not currently pay dividends.

What is Clinical Laserthermia Systems AB Class B’s EPS estimate?

Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Clinical Laserthermia Systems AB Class B have?

Clinical Laserthermia Systems AB Class B has 48,513,240 shares outstanding.

What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?

Clinical Laserthermia Systems AB Class B reported an EPS of -€0.035 in its last earnings report. Following the earnings report the stock price went down -3.734%.

Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?

Currently, no hedge funds are holding shares in DE:LS60

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description